|
1
|
Feng RM, Zong YN, Cao SM and Xu RH:
Current cancer situation in China: Good or bad news from the 2018
Global cancer statistics? Cancer Commun (Lond). 39:222019.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miller KD, Goding Sauer A, Ortiz AP,
Fedewa SA, Pinheiro PS, Tortolero-Luna G, Martinez-Tyson D, Jemal A
and Siegel RL: Cancer statistics for Hispanics/Latinos, 2018. CA
Cancer J Clin. 68:425–445. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li A, Zhang R, Zhang Y, Liu X, Wang R, Liu
J, Liu X, Xie Y, Cao W, Xu R, et al: BEZ235 increases sorafenib
inhibition of hepatocellular carcinoma cells by suppressing the
PI3K/AKT/mTOR pathway. Am J Transl Res. 11:5573–5585.
2019.PubMed/NCBI
|
|
4
|
Smith DK and Murphy BA: Lower levels of
education and household income mediate lower dental care
utilization among survivors of early life cancers. Prev Med Rep.
14:1008682019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu X, Xie C, Li A, Zhang Y, Liu X, Zhou
S, Shen J, Huo Z, Cao W, Ma Y, et al: BEZ235 enhances
chemosensitivity of paclitaxel in hepatocellular carcinoma through
inhibiting the PI3K/Akt/mTOR pathway. Am J Transl Res.
11:7255–7271. 2019.PubMed/NCBI
|
|
6
|
Yang Y, Yao JH, Du QY, Zhou YC, Yao TJ, Wu
Q, Liu J and Ou YR: Connexin 32 downregulation is critical for
chemoresistance in oxaliplatin-resistant HCC cells associated with
EMT. Cancer Manag Res. 11:5133–5146. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ye JZ, Yan SM, Yuan CL, Wu HN, Zhang JY,
Liu ZH, Li YQ, Luo XL, Lin Y and Liang R: GP73 level determines
chemotherapeutic resistance in human hepatocellular carcinoma
cells. J Cancer. 9:415–423. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhu YJ, Zheng B, Wang HY and Chen L: New
knowledge of the mechanisms of sorafenib resistance in liver
cancer. Acta Pharmacol Sin. 38:614–622. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang Y, Liu X, Zhang J, Xu Y, Shao J, Hu
Y, Shu P and Cheng H: Inhibition of miR-19a partially reversed the
resistance of colorectal cancer to oxaliplatin via PTEN/PI3K/AKT
pathway. Aging (Albany NY). 12:5640–5650. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kang HG, Wang BZ, Zhang J, Liu MR and Li
YX: Combination of temsirolimus and Adriamycin exhibits an enhanced
antitumor effect in hepatocellular carcinoma. Clin Res Hepatol
Gastroenterol. 41:197–203. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sun X, Su Y, He Y, Zhang J, Liu W, Zhang
H, Hou Z, Liu J and Li J: New strategy for in vitro activation of
primordial follicles with mTOR and PI3K stimulators. Cell Cycle.
14:721–731. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fruman DA, Chiu H, Hopkins BD, Bagrodia S,
Cantley LC and Abraham RT: The PI3K pathway in human disease. Cell.
170:605–635. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Aoki M and Fujishita T: Oncogenic roles of
the PI3K/AKT/mTOR axis. Curr Top Microbiol Immunol. 407:153–189.
2017.PubMed/NCBI
|
|
14
|
Grosbois J and Demeestere I: Dynamics of
PI3K and Hippo signaling pathways during in vitro human follicle
activation. Hum Reprod. 33:1705–1714. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chang L, Graham PH, Ni J, Hao J, Bucci J,
Cozzi PJ and Li Y: Targeting PI3K/Akt/mTOR signaling pathway in the
treatment of prostate cancer radioresistance. Crit Rev Oncol
Hematol. 96:507–517. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brown JS and Banerji U: Maximising the
potential of AKT inhibitors as anti-cancer treatments. Pharmacol
Ther. 172:101–115. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mehal W: NASH and HCC are driven by
different signaling pathways with a common regulator. Cell Metab.
29:3–4. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee JH, Lee HJ, Sim DY, Jung JH, Kim KR
and Kim SH: Apoptotic effect of lambertianic acid through
AMPK/FOXM1 signaling in MDA-MB231 breast cancer cells. Phytother
Res. 32:1755–1763. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Laughner E, Taghavi P, Chiles K, Mahon PC
and Semenza GL: HER2 (neu) signaling increases the rate of
hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel
mechanism for HIF-1-mediated vascular endothelial growth factor
expression. Mol Cell Biol. 21:3995–4004. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qu D, Weygant N, Yao J, Chandrakesan P,
Berry WL, May R, Pitts K, Husain S, Lightfoot S, Li M, et al:
Overexpression of DCLK1-AL increases tumor cell invasion, drug
resistance, and KRAS activation and can be targeted to inhibit
tumorigenesis in pancreatic cancer. J Oncol. 2019:64029252019.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Simioni C, Martelli AM, Cani A,
Cetin-Atalay R, McCubrey JA, Capitani S and Neri LM: The AKT
inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying
hyperphosphorylated AKT-1 and synergizes with conventional
chemotherapy. Oncotarget. 4:1496–1506. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu X, Liu J, Qiu H, Hao H, Zhu J and Peng
S: Combined inhibition of ACK1 and AKT shows potential toward
targeted therapy against KRAS-mutant non-small-cell lung cancer.
Bosn J Basic Med Sci. 21:198–207. 2021.PubMed/NCBI
|
|
23
|
Li YL, Weng HC, Hsu JL, Lin SW, Guh JH and
Hsu LC: The combination of MK-2206 and WZB117 exerts a synergistic
cytotoxic effect against breast cancer cells. Front Pharmacol.
10:13112019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu Y, Zhong Y, Long X, Zhu Z, Zhou Y, Ye
H, Zeng X and Zheng X: Deoxyshikonin isolated from Arnebia
euchroma inhibits colorectal cancer by down-regulating the
PI3K/Akt/mTOR pathway. Pharm Biol. 57:412–423. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang X, Wang X, Xu Y, Yan M, Li W, Chen J
and Chen T: Effect of nicastrin on hepatocellular carcinoma
proliferation and apoptosis through PI3K/AKT signalling pathway
modulation. Cancer Cell Int. 20:912020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jiao M and Nan KJ: Activation of PI3
kinase/Akt/HIF-1α pathway contributes to hypoxia-induced
epithelial-mesenchymal transition and chemoresistance in
hepatocellular carcinoma. Int J Oncol. 40:461–468. 2012.PubMed/NCBI
|
|
27
|
Ling S, Li J, Shan Q, Dai H, Lu D, Wen X,
Song P, Xie H, Zhou L, Liu J, et al: USP22 mediates the multidrug
resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1
signaling pathway. Mol Oncol. 11:682–695. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ma J, Xie SL, Geng YJ, Jin S, Wang GY and
Lv GY: In vitro regulation of hepatocellular carcinoma cell
viability, apoptosis, invasion, and AEG-1 expression by LY294002.
Clin Res Hepatol Gastroenterol. 38:73–80. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Elefantova K, Lakatos B, Kubickova J,
Sulova Z and Breier A: Detection of the mitochondrial membrane
potential by the cationic Dye JC-1 in L1210 cells with massive
overexpression of the plasma membrane ABCB1 drug transporter. Int J
Mol Sci. 19:19852018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tang X, Li A, Xie C, Zhang Y, Liu X, Xie
Y, Wu B, Zhou S, Huang X, Ma Y, et al: The PI3K/mTOR dual inhibitor
BEZ235 nanoparticles improve radiosensitization of hepatoma cells
through apoptosis and regulation DNA repair pathway. Nanoscale Res
Lett. 15:632020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Devanabanda B and Kasi A: Oxaliplatin.
StatPearls. Treasure Island (FL): StatPearls Publishing Copyright©
2020, StatPearls Publishing LLC; 2020
|
|
32
|
Tang X, Chen L, Li A, Cai S, Zhang Y, Liu
X, Jiang Z, Liu X, Liang Y and Ma D: Anti-GPC3 antibody-modified
sorafenib-loaded nanoparticles significantly inhibited HepG2
hepatocellular carcinoma. Drug Deliv. 25:1484–1494. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shen JH, Chen PH, Liu HD, Huang DA, Li MM
and Guo K: HSF1/AMPKα2 mediated alteration of metabolic phenotypes
confers increased oxaliplatin resistance in HCC cells. Am J Cancer
Res. 9:2349–2363. 2019.PubMed/NCBI
|
|
34
|
Liao X, Song G, Xu Z, Bu Y, Chang F, Jia
F, Xiao X, Ren X, Zhang M and Jia Q: Oxaliplatin resistance is
enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in
hepatocellular carcinoma. BMC Cancer. 20:312020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
He J, Ma J, Ren B and Liu A: Advances in
systemic lupus erythematosus pathogenesis via mTOR signaling
pathway. Semin Arthritis Rheum. 50:314–320. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mammana S, Bramanti P, Mazzon E, Cavalli
E, Basile MS, Fagone P, Petralia MC, McCubrey JA, Nicoletti F and
Mangano K: Preclinical evaluation of the PI3K/Akt/mTOR pathway in
animal models of multiple sclerosis. Oncotarget. 9:8263–8277. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nicoletti F, Fagone P, Meroni P, McCubrey
J and Bendtzen K: mTOR as a multifunctional therapeutic target in
HIV infection. Drug Discov Today. 16:715–721. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fagone P, Ciurleo R, Lombardo SD,
Iacobello C, Palermo CI, Shoenfeld Y, Bendtzen K, Bramanti P and
Nicoletti F: Transcriptional landscape of SARS-CoV-2 infection
dismantles pathogenic pathways activated by the virus, proposes
unique sex-specific differences and predicts tailored therapeutic
strategies. Autoimmun Rev. 19:1025712020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gong C, Ai J, Fan Y, Gao J, Liu W, Feng Q,
Liao W and Wu L: NCAPG promotes the proliferation of hepatocellular
carcinoma through PI3K/AKT signaling. Onco Targets Ther.
12:8537–8552. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xie Y and Zhong DW: AEG-1 is associated
with hypoxia-induced hepatocellular carcinoma chemoresistance via
regulating PI3K/AKT/HIF-1alpha/MDR-1 pathway. EXCLI J. 15:745–757.
2016.PubMed/NCBI
|
|
41
|
Li XZ, Sun YL, Cao LQ and Li MJ:
Oxaliplatin-rapamycin combination was superior to mono-drug in
treatment of hepatocellular carcinoma both in vitro and in vivo.
Neoplasma. 63:880–887. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liao B, Zhang Y, Sun Q and Jiang P:
Vorinostat enhances the anticancer effect of oxaliplatin on
hepatocellular carcinoma cells. Cancer Med. 7:196–207. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fu X, Wen H, Jing L, Yang Y, Wang W, Liang
X, Nan K, Yao Y and Tian T: MicroRNA-155-5p promotes hepatocellular
carcinoma progression by suppressing PTEN through the PI3K/Akt
pathway. Cancer Sci. 108:620–631. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang Y, Xie C, Li A, Liu X, Xing Y, Shen
J, Huo Z, Zhou S, Liu X, Xie Y, et al: PKI-587 enhances
chemosensitivity of oxaliplatin in hepatocellular carcinoma through
suppressing DNA damage repair pathway (NHEJ and HR) and
PI3K/AKT/mTOR pathway. Am J Transl Res. 11:5134–5149.
2019.PubMed/NCBI
|
|
45
|
Wang Y, Nie H, Zhao X, Qin Y and Gong X:
Bicyclol induces cell cycle arrest and autophagy in HepG2 human
hepatocellular carcinoma cells through the PI3K/AKT and
Ras/Raf/MEK/ERK pathways. BMC Cancer. 16:7422016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Li TT, Zhu D, Mou T, Guo Z, Pu JL, Chen
QS, Wei XF and Wu ZJ: IL-37 induces autophagy in hepatocellular
carcinoma cells by inhibiting the PI3K/AKT/mTOR pathway. Mol
Immunol. 87:132–140. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhu F, Jiang D, Zhang M and Zhao B:
2,4-Dihydroxy- 3′-methoxy-4′-ethoxychalcone suppresses cell
proliferation and induces apoptosis of multiple myeloma via the
PI3K/akt/mTOR signaling pathway. Pharm Biol. 57:641–648. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fang X, Yang D, Luo H, Wu S, Dong W, Xiao
J, Yuan S, Ni A, Zhang KJ, Liu XY and Chu L: SNORD126 promotes HCC
and CRC cell growth by activating the PI3K-AKT pathway through
FGFR2. J Mol Cell Biol. 9:243–255. 2017.PubMed/NCBI
|
|
49
|
Zhou M, Zhang Q, Zhao J, Liao M, Wen S and
Yang M: Phosphorylation of Bcl-2 plays an important role in
glycochenodeoxycholate-induced survival and chemoresistance in HCC.
Oncol Rep. 38:1742–1750. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Pan W, Li W, Zhao J, Huang Z, Zhao J, Chen
S, Wang C, Xue Y, Huang F, Fang Q, et al: lncRNA-PDPK2P promotes
hepatocellular carcinoma progression through the PDK1/AKT/Caspase 3
pathway. Mol Oncol. 13:2246–2258. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Jiang S, Wang Q, Feng M, Li J, Guan Z, An
D, Dong M, Peng Y, Kuerban K and Ye L: C2-ceramide enhances
sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and
Erk signaling pathways in HCC cells. Appl Microbiol Biotechnol.
101:1535–1546. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Sui Y, Zheng X and Zhao D: Rab31 promoted
hepatocellular carcinoma (HCC) progression via inhibition of cell
apoptosis induced by PI3K/AKT/Bcl-2/BAX pathway. Tumour Biol.
36:8661–8670. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mendez-Blanco C, Fondevila F,
Garcia-Palomo A, Gonzalez-Gallego J and Mauriz JL: Sorafenib
resistance in hepatocarcinoma: Role of hypoxia-inducible factors.
Exp Mol Med. 50:1–9. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Gong J, Zhou S and Yang S: Vanillic Acid
Suppresses HIF-1α expression via inhibition of mTOR/p70S6K/4E-BP1
and Raf/MEK/ERK pathways in human colon cancer HCT116 cells. Int J
Mol Sci. 20:4652019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Xu LF, Ni JY, Sun HL, Chen YT and Wu YD:
Effects of hypoxia-inducible factor-1α silencing on the
proliferation of CBRH-7919 hepatoma cells. World J Gastroenterol.
19:1749–1759. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Chen J, Bai M, Ning C, Xie B, Zhang J,
Liao H, Xiong J, Tao X, Yan D, Xi X, et al: Gankyrin facilitates
follicle-stimulating hormone-driven ovarian cancer cell
proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway.
Oncogene. 35:2506–2517. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ferrin G, Guerrero M, Amado V,
Rodriguez-Peralvarez M and De la Mata M: Activation of mTOR
signaling pathway in hepatocellular carcinoma. Int J Mol Sci.
21:12662020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Duan Y, Haybaeck J and Yang Z: Therapeutic
potential of PI3K/AKT/mTOR pathway in gastrointestinal stromal
tumors: Rationale and progress. Cancers (Basel). 12:29722020.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Steelman LS, Martelli AM, Cocco L, Libra
M, Nicoletti F, Abrams SL and McCubrey JA: The therapeutic
potential of mTOR inhibitors in breast cancer. Br J Clin Pharmacol.
82:1189–1212. 2016. View Article : Google Scholar : PubMed/NCBI
|
